Eli Lilly and Company (LLY) Stock Forecast & Price Target

$742.51 -4.47 (-0.60%)

Closing price 09/24/2025 03:59 PM Eastern

Extended Trading

$741.15 -1.36 (-0.18%)

As of 09/24/2025 07:59 PM Eastern

Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
9

Buy
15

Based on 24 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 9 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$939.61
26.55% Upside

According to the 24 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $939.61. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 26.55% from the current price of $742.51.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

Type	Current Forecast 9/25/24 to 9/25/25	1 Month Ago 8/26/24 to 8/26/25	3 Months Ago 6/27/24 to 6/27/25	1 Year Ago 9/26/23 to 9/25/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)
Hold	9 Hold rating(s)	7 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$939.61	$950.17	$1,011.61	$977.35
Forecasted Upside	26.55% Upside	29.29% Upside	30.33% Upside	5.66% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.78	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	26.55% Upside	1,730.48% Upside	11.58% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/17/2025	Berenberg Bank 2 of 5 stars	Kerry Holford Not Rated	Reiterated Rating	Buy ➝ Hold	$970.00 ➝ $830.00	+8.70%
9/16/2025	JPMorgan Chase & Co. 2 of 5 stars	Chris Schott Not Rated	Lower Target	Overweight	$1,100.00 ➝ $1,050.00	+40.33%
8/27/2025	HSBC 2 of 5 stars	Rajesh Kumar Not Rated	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00	-4.75%
8/27/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Sell ➝ Hold
8/17/2025	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00	-0.22%
8/17/2025	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
8/14/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
8/13/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$975.00 ➝ $825.00	+25.02%
8/13/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$942.00 ➝ $875.00	+35.19%
8/11/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,010.00 ➝ $900.00	+40.51%
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
8/8/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,050.00 ➝ $895.00	+42.63%
8/7/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
8/7/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Market Perform Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00	+11.07%
7/10/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$1,133.00 ➝ $1,135.00	+43.19%
6/5/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	H. Engel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/1/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
4/8/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$892.00 ➝ $888.00	+20.24%
2/3/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,029.00 ➝ $1,038.00	+27.51%
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,250.00 ➝ $1,190.00	+47.25%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$997.00	+24.17%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$1,000.00	+27.23%
11/4/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Baker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
10/31/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$1,025.00 ➝ $975.00	+16.30%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$1,100.00	+20.04%
9/5/2024	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$1,001.00 ➝ $1,101.00	+30.36%
6/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$994.00 ➝ $1,015.00	+12.98%
5/14/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$770.00 ➝ $840.00	+11.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:41 AM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 24, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

The current stock price is around $700, reflecting a strong market position and investor confidence.
Eli Lilly and Co reported impressive earnings, with a significant year-over-year revenue increase of 37.6%, indicating robust business growth.
The company has a high return on equity of 92.72%, showcasing effective management and profitability relative to shareholder equity.
Analysts have a generally positive outlook, with an average rating of "Moderate Buy" and a price target of approximately $939.61, suggesting potential for price appreciation.
Recent upgrades from major financial institutions indicate growing confidence in the company's future performance.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

The stock has experienced fluctuations, with a 52-week high of $939.30 and a low of $623.78, indicating volatility that could concern risk-averse investors.
Recent downgrades from some analysts, including a reduction in price targets, may signal caution regarding the stock's near-term performance.
The company's debt-to-equity ratio of 1.86 suggests a higher level of debt compared to equity, which could pose risks in economic downturns.
Despite strong earnings, the high P/E ratio of 48.84 may indicate that the stock is overvalued relative to its earnings, which could deter value-focused investors.
Market conditions and competition in the pharmaceutical industry can impact future growth, making it essential for investors to consider external factors.

LLY Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $939.61, with a high forecast of $1,190.00 and a low forecast of $700.00.
: 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 9 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
: According to analysts, Eli Lilly and Company's stock has a predicted upside of 26.55% based on their 12-month stock forecasts.
: Over the previous 90 days, Eli Lilly and Company's stock had 3 upgrades and 3 downgrades by analysts.
: Eli Lilly and Company has been rated by research analysts at Berenberg Bank, Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, DZ Bank, Guggenheim, Hsbc Global Res, HSBC, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, and UBS Group in the past 90 days.
: Analysts like Eli Lilly and Company less than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.67 while the average consensus rating score for "medical" companies is 2.78. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:LLY) was last updated on 9/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target